Reply to M.S. Copur et al

Affiliations

Comment

Gregory P Kalemkerian et al. J Clin Oncol. 2018.

. 2018 Jul 1;36(19):2007.

doi: 10.1200/JCO.2018.78.9834. Epub 2018 May 15.

¹ Gregory P. Kalemkerian, University of Michigan, Ann Arbor, MI; and Navneet Narula, New York University, New York, NY.

No abstract available

Comment on

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Kalemkerian GP, et al. J Clin Oncol. 2018 Mar 20;36(9):911-919. doi: 10.1200/JCO.2017.76.7293. Epub 2018 Feb 5. J Clin Oncol. 2018. PMID: 29401004
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.
Copur MS, Crockett D, Gauchan D, Ramaekers R, Mleczko K. Copur MS, et al. J Clin Oncol. 2018 Jul 1;36(19):2006. doi: 10.1200/JCO.2018.78.8240. Epub 2018 May 15. J Clin Oncol. 2018. PMID: 29763342 No abstract available.